| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 5.4 | 6.2 |
| Gross profit | 1.5 | 2.7 |
| Profit before tax | -5.0 | -3.2 |
| Net income | -5.1 | -3.2 |
| EPS (diluted, $ a share) | $-1.32 | $-2.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -12.4% |
|---|---|
| Gross margin | 27.4% |
| Operating margin | -110.0% |
10-Q filed with the SEC, NASDAQ: LFWD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lifeward Ltd.: key numbers
- Share price
- $3.10Close, Nov 17
- Market cap
- $8.8M
- Shares outstanding
- 2.84MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lifeward Ltd.
All →Lifeward Financial Results
Lifeward Ltd. reported Q3 2026 financial results, highlighted by an 18% year-over-year increase in AlterG revenue to $3.6 million. The company is transitioning its ReWalk exoskeleton business to a capital-efficient channel-partner distribution model, including a pilot program with Ottobock Care, to expand patient access and reduce operating expenses.
- Term
- Q3 2026
“Our third quarter results reflect the continued momentum of AlterG, which delivered its second consecutive quarter of double-digit year-over-year revenue growth. We are also making significant progress in our strategic transition of ReWalk to a channel-partner model, which we believe is the most effective way to scale this business and bring our life-changing technology to more patients.”
Larry Jasinski, Chief Executive Officer
“We remain focused on driving commercial execution and managing our resources effectively as we advance our transition to a channel-partner model for ReWalk. We believe this model will allow us to reach more patients while improving our operating efficiency and cash flow over the long term.”
Ronen Tsimerman, Chief Financial Officer
Lifeward Shareholder Meeting
Lifeward Ltd. held its 2026 Annual and Extraordinary General Meeting of Shareholders on October 30, 2026. Shareholders approved the re-election of Haggai Zamir and Avi Gabay as Class III directors, the election of Ariel Kallner as an external director, and compensation packages for directors and Interim CEO Josh Hexter; however, Proposal 6 did not receive the requisite votes for approval.
Lifeward Executive Compensation
Lifeward Ltd. appointed Ronen Tsimerman as Chief Financial Officer, effective November 1, 2026. The appointment includes an employment agreement with a gross monthly base salary of NIS 70,000 and a target annual performance-based bonus of at least four monthly salaries, subject to shareholder approval of a renewed compensation policy.
- Counterparty
- Ronen Tsimerman
Lifeward Leadership Change
Rami Aviram, who was previously appointed as Chief Financial Officer effective November 1, 2026, has informed Lifeward Ltd. that he will no longer join the company. Josh Hexter will continue to serve as the interim principal financial and accounting officer while the company resumes its search for a permanent CFO.
- Counterparty
- Rami Aviram
Lifeward Leadership Change
Lifeward Ltd. announced that Almog Adar's departure as CFO became effective on September 30, 2026. Interim CEO Josh Hexter has been designated to serve as the interim principal financial and accounting officer until Rami Aviram assumes the CFO role on November 1, 2026.
Lifeward Shareholder Meeting
Lifeward Ltd. has scheduled its 2026 Annual and Extraordinary General Meeting of Shareholders for October 30, 2026. Because the meeting date is more than 30 days from the anniversary of the prior year's meeting, the company established September 23, 2026, as the deadline for shareholder proposals and director nominations.